Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 10;13(10):e074317.
doi: 10.1136/bmjopen-2023-074317.

Efficacy of automated insulin delivery (AID) systems in type 1 diabetes: protocol of a systematic review and network meta-analysis of outpatient randomised controlled trials

Anna Stahl-Pehe  1   2 , Sabrina Schlesinger  3   2 , Oliver Kuss  3   2 , Nafiseh Shokri-Mashhadi  3   2 , Christina Bächle  3   2 , Klaus-D Warz  4 , Jutta Bürger-Büsing  5 , Reinhard Holl  2   6 , Olaf Spörkel  3   2 , Joachim Rosenbauer  3   2
Affiliations

Efficacy of automated insulin delivery (AID) systems in type 1 diabetes: protocol of a systematic review and network meta-analysis of outpatient randomised controlled trials

Anna Stahl-Pehe et al. BMJ Open. .

Abstract

Introduction: Automated insulin delivery (AID), also known as artificial pancreas system or 'closed-loop system', represents a novel option for current treatments for type 1 diabetes (T1D). The objective of this systematic review and meta-analysis is to assess the efficacy of AID systems in comparison with current intensified insulin therapy for glycaemic control and patient-reported outcomes in individuals with T1D.

Methods and analysis: Studies will be eligible if they are randomised controlled trials (RCTs) in people with T1D of all ages, and if they compare an AID system for self-administration during the day and night period with any other type of insulin therapy for at least 3 weeks. The primary outcome will be time in the glucose target range of 70-180 mg/dL. A systematic review will be conducted in the MEDLINE, Embase, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov registries from their inception dates. Two authors will independently screen all references based on titles and abstracts against the eligibility criteria. For data extraction, standard forms will be developed and tested before extraction. All information will be assessed independently by at least two reviewers. The risk of bias of the included studies will be assessed using the Cochrane Risk of Bias 2 tool. The data synthesis will include a random-effects pairwise and network meta-analysis (NMA) in a frequentist framework. Where applicable and if sufficient RCTs are available, sensitivity analyses will be performed, and heterogeneity and publication bias will be assessed. The certainty of evidence from the NMA will be evaluated following the Grading of Recommendations Assessment, Development, and Evaluation working group guidance.

Ethics and dissemination: No ethical approval is needed. The results will be reported to the funder, presented in a peer-reviewed scientific journal and at conferences, and disseminated via press release, social media and public events.

Prospero registration number: CRD42023395492.

Keywords: diabetes & endocrinology; quality of life; systematic review.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

See all similar articles

References

    1. Gregory GA, Robinson TIG, Linklater SE, et al. . Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a Modelling study. Lancet Diabetes Endocrinol 2022;10:741–60. 10.1016/S2213-8587(22)00218-2 - DOI - PubMed
    1. International Diabetes Federation . Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence. Brussels: International Diabetes Federation, 2011.
    1. American Diabetes Association . Glycemic targets: standards of medical care in diabetes - 2020. Diabetes Care 2020;43:S66–76. 10.2337/dc20-S006 - DOI - PubMed
    1. Trevitt S, Simpson S, Wood A. Artificial Pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development J Diabetes Sci Technol 2016;10:714–23. 10.1177/1932296815617968 - DOI - PMC - PubMed
    1. ElSayed NA, Aleppo G, Aroda VR, et al. . 7. diabetes technology: standards of care in Diabetes-2023. Diabetes Care 2023;46:S111–27. 10.2337/dc23-S007 - DOI - PMC - PubMed

Publication types